Unpublished Presentations


27. Bigner, D.D.: Oncornavirus, organ specific and possible idiotypic antigen expression in human glioma cells, University of Virginia School of Medicine, Charlottesville, Virginia, September 8, 1977.


34. Preissig, S.H. and Bigner, D.D.: Correlation of morphologic and cell biologic features of human glioma cells with their neoplastic potential. The Wallenberg Laboratory and Institute of Pathology, University of Uppsala, Sweden, June 1, 1979.


44. Bigner, D.D.: Human glioma antigens, Ohio State University Neuroscience Society, Columbus, Ohio, November 6, 1980.


55. Bigner, D.D.: Antigenic heterogeneity of human glioblastoma multiforme, Department of Pathology, University of Texas at San Antonio, November 6, 1981.


62. Bigner, D.D.: Monoclonal antibodies against human glioma associated antigens; and heterogeneity of therapeutic responsiveness of human gliomas in athymic mice, Department of Pathology, Medical College of Virginia, Richmond, Virginia, October 29, 1982.


70. Bigner, D.D.: Chairman, Monoclonal Antibodies and Brain Tumor Biology, Fifth Brain Tumor Research and Therapy Conference, Monterey, California, October 23 27, 1983.


96. Bigner, D.: Where Has the Biological Revolution Taken Us Toward Progress with Malignant Brain Tumors. The Milton S. Hershey Medical Center Neuroscience Seminar, Pennsylvania State University, School of Medicine, Hershey, Pennsylvania, February 20, 1986.


108. Bigner, D.D., Discussion Leader, Brain Tumor Classification Section, Preuss Foundation Conference on Recent Advances in Brain Tumor Research, October 15, 1986.


111. Bigner, D.D.: Visiting Professor Seminar, Pitfalls and anticipations in the use of monoclonal antibodies against brain tumors, Department of Neuro oncology, M.D. Anderson Hospital and Tumor Institute, Houston, Texas, November 13, 1986; and


123. Bigner, D.D. and Bigner, S.: Cytogenetics and molecular genetics of malignant glial tumors; and


136. Bigner, D.D.: Visiting Lecturer. Genetic markers of cytogenetic and other genetic alterations in central nervous system tumors of adults and children; and


143. Bigner, D.D.: The 1990's will be the decade for translation of basic discoveries into meaningful clinical progress in neuro oncology. Department of Neurosurgery Grand Rounds, University of Kentucky, Lexington, Kentucky, January 24, 1991; and


146. Bigner, D.D.: Visiting Professor, Can levels and regulation of a drug resistance enzyme, such as methylguanine methyltransferase, predict or be manipulated to determine glioma response to chemotherapeutic agents? Special Seminar of the Brain Tumor Group: Harvard Medical School, Boston, Massachusetts, February 27, 1991; Brain Tumor Research Seminar, February 27-28, 1991.


156. Chairman, Brain Tumor Platform Session, American Association of Neuropathologists, St. Louis, Missouri, June 17, 1992.


164. Bigner, D.D.: Radiolabeled Monoclonal Antibodies and Immunotoxins in the Treatment of Primary and Metastatic CNS Tumors. Case Western Reserve School of Medicine, Cleveland Clinic, June 14, 1994.


174. Bigner, D.D.: Targeted therapy of cancer against an oncogene deletion mutant gene product. Case Western Reserve School of Medicine, Cleveland, Ohio, April 17, 1996.


196. Bigner, D.D.: Chairman, Session of Tumor Biology and Immunology, Thirteenth International Conference on Brain Tumor Research and Therapy, Sapporo, Japan, October 5, 1999.


266. Bigner, D.D.: Molecularly Targeted Immunotherapy of Brain Tumors. BTRC Lecture, Western Hospital, University of Toronto. Toronto, Canada, February 3, 2005.


300. Bigner, D.D. Choosing Appropriate Molecular Targets for Malignant Brain Tumor Therapy. Emory University, Atlanta, Georgia, June 1, 2007.


332. Bigner, D.D. Southeastern Brain Tumor Foundation Talk. Southeastern Brain Tumor Foundation Grant Award Ceremony. Emory University, Atlanta, Georgia, March 19, 2010.


